StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/307% above fair value
$63.34−1.54 (-2.37%)

Close on Nov 20, 2026Market cap $9.70BP/E 23.1Yield –

TG Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

TG Therapeutics's pe ratio was 24.0× on Nov 11, 2026, against 12.0× a year earlier. Over the last 4 years it ranged from 0.2× to 303.4×, with a median of 19.8×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202624.0×+13.3
2025Dec 31, 202510.7×−30.4
2024Oct 31, 202441.1×+40.4
2012Jan 31, 20120.7×+0.5
2011Dec 30, 20110.2×–

More TG Therapeutics figures

See a number that looks wrong?